404

The page you requested doesn't exist

We could not locate the page: /assets/performance-DG8yJL7T.js

Try one of the featured posts or search the archive below.

Featured Posts

Sectors in briefSectors in brief
Comparing the Pharmaceutical Glass Packaging Players

Comparing the Pharmaceutical Glass Packaging Players

Digging into Schott Pharma AG, Gerresheimer AG and Stevanato Group fundamentals

The Octopus Value Investing
The Octopus Value Investing
Schott Pharma AGSchott Pharma AG
#1 Schott Pharma - Qualitative Analysis

#1 Schott Pharma - Qualitative Analysis

Insights on the Pharmaceutical Glass Packaging Leader

The Octopus Value Investing
The Octopus Value Investing
Schott Pharma AGSchott Pharma AG
#2 Schott Pharma AG - Quantitative Analysis

#2 Schott Pharma AG - Quantitative Analysis

Looking into the fundamentals of the pharma glass packaging leader

The Octopus Value Investing
The Octopus Value Investing

Archive

PandoraPandora
+1+1
Pandora A/S - 2024 Earnings Review

Pandora A/S - 2024 Earnings Review

Another Year Surpassing the Expectations Set

The Octopus Value Investing
The Octopus Value Investing
Sectors in briefSectors in brief
#5 Sectors in Brief - Pharmaceutical Packaging Assembly

#5 Sectors in Brief - Pharmaceutical Packaging Assembly

Searching for Investing Opportunities in Another Sector of the Pharmaceutical Industry

The Octopus Value Investing
The Octopus Value Investing
Earnings ReviewEarnings Review
+1+1
Novo Nordisk A/S - 2024 Earnings Review

Novo Nordisk A/S - 2024 Earnings Review

Hope for Recovery After a Challenging Semester: Overcoming 'Everything That Went Wrong

The Octopus Value Investing
The Octopus Value Investing
Lonza Group AGLonza Group AG
+1+1
Lonza Group AG - 2024 Earnings Review

Lonza Group AG - 2024 Earnings Review

Lonza Group AG: Resilient Performance Amid Strategic Investments and Cost Discipline

The Octopus Value Investing
The Octopus Value Investing
Schott Pharma AGSchott Pharma AG
+1+1
Schott Pharma AG - 23/24 Earnings Review

Schott Pharma AG - 23/24 Earnings Review

Short-Term Fears Taking over a Earnings Report Within Expectations

The Octopus Value Investing
The Octopus Value Investing
The Octopus PortfolioThe Octopus Portfolio
#3 The Journey of Compounding - 2024 Letter to Readers

#3 The Journey of Compounding - 2024 Letter to Readers

2024 Annual Review to all The Octopus Value Investing readers

The Octopus Value Investing
The Octopus Value Investing
News & Trending TopicsNews & Trending Topics
+1+1
CagriSema Phase III Results Review

CagriSema Phase III Results Review

Novo Nordisk Stock Plunge: Overreaction or Justified?

The Octopus Value Investing
The Octopus Value Investing
MiscellaneousMiscellaneous
+1+1
What Does It Mean for a Drug to Be Regulatory Approved?

What Does It Mean for a Drug to Be Regulatory Approved?

The Differential Quality of Regulatory Approved Drugs

The Octopus Value Investing
The Octopus Value Investing
MiscellaneousMiscellaneous
Hims&Hers Health: My Take

Hims&Hers Health: My Take

My Rationale to Drop Hims&Hers Health Investment Case

The Octopus Value Investing
The Octopus Value Investing
PandoraPandora
+3+3
Q3 2024 Earnings Recap

Q3 2024 Earnings Recap

Earnings Review Compilation of Novo Nordisk, Pandora & Lonza AG

The Octopus Value Investing
The Octopus Value Investing
Schott Pharma AGSchott Pharma AG
#2 Schott Pharma AG - Quantitative Analysis

#2 Schott Pharma AG - Quantitative Analysis

Looking into the fundamentals of the pharma glass packaging leader

The Octopus Value Investing
The Octopus Value Investing
Schott Pharma AGSchott Pharma AG
#1 Schott Pharma - Qualitative Analysis

#1 Schott Pharma - Qualitative Analysis

Insights on the Pharmaceutical Glass Packaging Leader

The Octopus Value Investing
The Octopus Value Investing
FirstBack
12345
Next Last